EVFM Evofem Biosciences Inc.

4.09
+0.26  (+7%)
Previous Close 3.83
Open 3.79
Price To Book -6.2
Market Cap 144699460
Shares 35,378,841
Volume 32,933
Short Ratio
Av. Daily Volume 29,940

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 4Q 2019.
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
Phase 3 data released December 17, 2018. Primary endpoint met. NDA to be refiled 2Q 2019.
Amphora - AMPOWER
contraceptive vaginal gel

Latest News

  1. STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evofem Biosciences, Inc. – EVFM
  2. PDL BioPharma Announces Equity Investment in Evofem Biosciences
  3. Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
  4. Evofem Biosciences raises $80m for new hormone-free contraceptive
  5. Evofem Biosciences to Present at Needham Healthcare Conference
  6. Evofem Biosciences to Present at Upcoming Investor Conferences
  7. Edited Transcript of EVFM earnings conference call or presentation 1-Mar-19 4:00pm GMT
  8. Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
  9. Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019
  10. Evofem Biosciences, Amphora a Potential New Birth Control, Analysts Review and Target
  11. Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
  12. Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT
  13. The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
  14. Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
  15. Evofem Shares Up as Birth Control Gel Succeeds in Phase III
  16. Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals
  17. 4 Stocks Providing Investor Opportunity Right Now
  18. Evofem's hormone-free birth control gel meets main goal in key study
  19. Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
  20. Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018